|Editorial  board | About the Journal   | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code |   Contact  |

Acta Medica Medianae
Vol. 48, No1 , Januar, 2009
UDK 61
YU ISSN 0365-4478


Correspondence to:
Ivana Damnjanović

Bulevar Nemanjića 76/34, Niš

Tel.:064 2412003









Original article


Pharmacokinetic and Pharmacodynamic modelling of Base Insulins and Analogs


Ivana Damnjanovic, Radmila Velickovic-Radovanovic, Aleksandra Catic-Djordjevic, Radivoj Kocic, Vojislav Ciric,  Irena Conic and Ljiljana Bjelakovic



Medicinski fakultet u Nišu1

Institut za farmakokinetiku Medicinskog fakulteta u Nišu2

Klinika za endokrinologiju, dijabetes i bolesti metabolizma Kliničkog centara u Nišu3

Klinika za onkologiju Kliničkog centra u Nišu4


Pharmacokinetic modeling implies establishing the medicine dosage regime based on the anticipated course of the effect, depending on the given time. It is based on measuring possible pharmacodynamic parameters that correlate with pharmacokinetic data.

Taking into consideration the latest discoveries on the pharmacokinetics of the base insulins and analogs, the primary aim of this paper was to compare the variability of their pharmacokinetic profile by using therapy monitoring in the patients suffering from the secondary insulin-dependent diabetes mellitus, type II. The secondary aims were: examining the influence of obesity, age and sex onto the pharmacokinetics (PK) of  the applied insulins, and comparing therapeutic efficiency of the examined insulin analogs with NPH insulin.

The research was performed at the Endocrinology Clinic, Clinical Center Nis, and it included 60 patients suffering from the secondary insulin-dependent diabetes mellitus, type II.  

The patients were on therapy including the use of NPH insulins for more than a year. All the patients were divided into two therapy groups, with the previous suspension of the insulin therapy:30 patients on therapy including the use of “glarginee” insulin and 30 patients on therapy including the use of “detemir” insulin.

By means of pharmacokinetic-pharmacodynamic analog estimation in this research, after three months, a statistically significant pharmacodynamic (PD) effect was determined, in the sense of a significant drop in the glycaemia and glycolised hemoglobin value. Acta Medica Medianae 2008;47(4):15-19.


Key words: Pharmacokinetic, Pharmacodynamic, modelling, NPH insulin, detemir, insulin, glarginee